Summary Abnormalities of the EGF receptor and/or the related ERBB2 receptor occur in a significant proportion of cases of human breast cancer and are important influences in the behaviour of this tumour type.
A great deal of progress has been made in understanding the oncogenes and growth factors which are involved in the molecular pathogenesis of breast cancer, allowing the development of new markers for patient selection and prognosis and potentially the identification of new targets for therapy. The type 1 family of receptor tyrosine kinases including the epidermal growth factor receptor (EGFR) and the ERBB2 (or HER2) protein have been recognised as being particularly important influences in breast cancer (Gullick 1990a ). Both of these receptor proteins are expressed at low levels on normal breast epithelial and myoepithelial cells and are often overexpressed in breast cancer. Patients with tumours in which there is elevated EGFR expression have a relatively poor prognosis with shorter relapse-free survival and overall survival (Sainsbury et al., 1987; Costa et al., 1988) . Overexpression of the ERBB2 protein is also a marker of poor prognosis for node-positive disease (Slamon et al., 1987) and probably also for node-negative disease (Perren, 1991) . More exciting, however, is the accumulating evidence that the ERBB2 receptor protein has potential as a target for antibody-directed therapy (Shepard et al., 1991) and other approaches such as inhibition of receptor dimerisation and tyrosine kinase function (Gullick 1990b) .
A new member of the type 1 receptor family, ERBB3, was cloned by two groups (Kraus et al., 1989; Plowman et al., 1990 ) and found to be expressed at the RNA level in a number of tumour cell lines, including 6 out of 17 breast cancer cell lines (Plowman et al., 1990 Southern blot analysis 10 jig DNA from each of the paired normal/tumour samples was digested with restriction enzymes EcoRI or PstI, electrophoresed through 0.8% agarose gel and blotted onto nylon membranes (Hybond-N+, Amersham). Hybridisation was performed with a cDNA probe for ERBB3 labelled with 32P-ATP by the random primer method, and filters washed at high stringency in 0.1 x SSC/0. 1% SDS at 65°C for 10 min. The ERBB3 probe was generated by PCR from a placental cDNA library and represents positions 3625 to 4138 of the sequence reported by Kraus et al. (1989) , including sequences encoding the C-terminal 170 amino acids of the ERBB3 protein. The 513 base pair fragment was cloned in Bluescript and double-stranded sequence analysis performed to confirm that it conformed in every respect to the ERBB3 sequence published by Kraus et al. (1989) . It is completely specific for ERBB3 in hybridisation analysis of human DNA and RNA.
After autoradiography the filters were stripped and reprobed with a probe for ,-actin (Cleveland et al., 1980) . RNA analysis RNA was extracted from cultured cells and Northern blots prepared by standard techniques (Ausubel et al., 1991) . Blots were hybridised with the ERBB3 cDNA probe as described above. After autoradiography the filters were stripped and reprobed with for ,-actin.
Immunohistochemistry
The immunohistochemical staining of paraffin sections was carried out using the affinity-purified rabbit polyclonal antisera to peptide sequences of ERBB3 as previously described 
Statistical analysis
Relationships between variables were analysed using the Chisquared test. Survival curves were calculated using the method of Kaplan & Meier (Peto et al., 1977) and differences between curves were analysed by the logrank test.
Results
We observed a wide range in the level of expression of ERBB3 mRNA and protein in the various breast cell lines examined (Table I and Figure 2 ). The immortalised, nonmalignant cell lines, such as MTSV-1.7, showed barely detec- (Figure 2 ). There was no abnormality of structure or gene copy number observed on Southern blot analysis of DNA from any of the cell lines. In the normal breast tissue samples examined we found that there was finely granular cytoplasmic immunoreactivity of weak to moderate intensity in the luminal epithelial cells of the ducts and acini throughout all phases of the menstrual cycle, and in occasional cases there was also weak immunoreactivity in the myoepithelial cells.
In the 36 tumours analysed by Southern blot we detected no abnormality of gene structure or copy number (data not shown), but immunohistochemistry showed that there was wide variation in the level of ERBB3 expression in the primary breast cancer specimens. Immunohistochemistry with the two anti-ERBB3 antibodies gave concordant results but since the level of background staining of stromal tissues was found to be less with 49.3 than with 61.3 in pilot studies on 36 cases, this antibody was used for the larger series of 195 cases (Table II) . Twenty six (13%) of these 195 cases showed no detectable immunoreactivity in tumour cells (i.e., less than normal), while at the other end of the spectrum 42 cases (22%) showed cytoplasmic staining of much greater intensity than normal breast epithelium (Figure 3) . The frequency of high expression was higher in infiltrating ductal carcinomas (39/168 cases, 23%) than in invasive lobular carcinomas (3/24 cases, 12.5%), but this difference is not statistically significant. We have seen only one case of breast cancer displaying membrane staining with the anti-ERBB3 antiserum 49.3. In the remaining cases the level of immunoreactivity in the tumour cells was similar to that observed in normal breast epithelium.
There was a statistically significant association between strong ERBB3 immunoreactivity (greater than normal breast epithelium) and the presence of lymph node metastases (P = 0.02, Table III ). Those cases with overexpression of ERBB3 showed no difference in survival compared to those cases expressing normal or low levels, regardless of nodal status (Figure 3 ). There was no association between the level of expression of ERBB3 and tumour size or histological grade of invasive ductal carcinomas (Table III) . We found no correlation between ERBB3 immunoreactivity and immunoreactivity for EGF receptor, ERBB2 and p53, nor with steroid receptor status. very low levels of ERBB3 expression were detected in the nonmalignant immortal cell lines, while higher levels were found in the cell lines derived from tumours. None of these cell lines showed amplification or rearrangement of the ERBB3 gene, and nor did any of the primary breast cancers which were examined by Southern blot.
Expression of ERBB3 showed a wide variation in the tumour biopsies, some samples being completely negative by immunohistochemistry while others were stained much more strongly than normal breast epithelium. The immunoreactivity was nearly always cytoplasmic and finely granular and, in contrast to the usual patterns of ERBB2 and EGF receptor overexpression in breast cancer, we saw only one case of membrane staining for ERBB3. However, we have observed more frequent membrane immunoreactivity for ERBB3 in pancreatic cancers and gastric cancers . Membrane immunoreactivity for the related receptor protein ERBB2 is characteristically seen in tumour cases with very high levels of expression associated with gene amplification while cytoplasmic staining is usually indicative of lower levels of expression (Venter et al., 1987) . Our finding of cytoplasmic immunoreactivity may imply that the level of overexpression of the ERBB3 protein is relatively modest in breast cancer. We found no evidence of ERBB3 gene amplification in these tumours and cell lines, and similar findings were reported in 17 breast cancer lines by Kraus et al. (1989) . However, the fact that immunoreactivity for this protein, postulated to be a transmembrane receptor, is generally confined to the cytoplasm is intriguing but not necessarily surprising. There is evidence that substantial proportions of EGFR and ERBB2 proteins may be in cellular pools other than the plasma membrane, suggesting that cytoplasmic immunoreactivity may be significant. Indeed, Kumar et al. (1991) have recently shown that even in a cell line expressing high levels of ERBB2 from multiple copies of the gene only about 19% of the receptor protein was expressed on the cell membrane, the remainder being in other cell fractions.
Overexpression of the ERBB3 protein in these breast cancers was independent of the level of expression of either the EGF receptor or the ERBB2 receptor. Both of the latter have been reported to represent prognostic markers when found overexpressed in breast cancer (reviewed in Gullick, 1990a) , but in this present series ERBB3 overexpression was not found to correlate with disease outcome. However, it was associated with the presence of lymph node metastases. Our previous experience with ERBB2 (Gullick et al., 1991b) suggests that substantially larger series of cases will be required to reliably confirm or exclude the utility of ERBB3 overexpression as a prognostic marker in breast cancer. Our report shows that while high expression of this protein occurs in a substantial proportion of breast cancers the majority of cases show normal or low levels of expression. Whether ERBB3 represents an oncogene involved in breast cancer remains uncertain.
